In prostate cancer, other techniques have been developed, such as therapeutic dendritic cell (DC) vaccines activated against antigens specific to prostatic tumor cells [15]; of these, the most widely used are prostatic acid phosphatase (PAP), PSA, PSMA, prostatic stem cell antigen (PSCA), human telomerase reverse transcriptase (hTERT), and T-cell receptor gamma (TARP) [16]. This evidence concerns the gene PSCA and prostate neoplasm.